Cantor Fitzgerald initiated coverage of Eli Lilly (LLY) with an Overweight rating and $975 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Novo submits obesity pill for FDA approval, BioPharma Dive reports
- Eli Lilly & Co: Strong Market Position and Growth Potential with Orforglipron Launch
- Stock Market Recap: Eli Lilly Soars, UnitedHealth Crashes, Financials Lead Sector Gains
- Eli Lilly’s Stock Soars Amid Promising Drug Trials
- Eli Lilly (LLY) Pledges to Manufacture Weight-Loss Pill in the U.S.